Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

UnitedHealth Group, AbbVie, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks refer to equities in companies that are ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Lilly has revealed that subjects with Crohn's disease have achieved long-term clinical and endoscopic outcomes with Omvoh in the VIVID-2.

Good morning, thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call ... including 17 major publications in top tier medical journals. We received regulatory approvals for ...

Eli Lilly (LLY) came out with quarterly earnings of $5.32 per share, beating the Zacks Consensus Estimate of $5.03 per share. This compares to earnings of $2.49 per share a year ago. These figures ...